PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933356
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933356
Pediatric Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of pediatric vaccines Market
The global pediatric vaccines market was valued at USD 46.86 billion in 2025 and is projected to grow to USD 50.46 billion in 2026, reaching USD 121.46 billion by 2034, with a CAGR of 11.61% during the forecast period. North America dominated the market in 2025 with a share of 51.84%, driven by advanced healthcare infrastructure, strong government support, and robust vaccination programs. Pediatric vaccines play a critical role in preventing life-threatening diseases in children, including malaria, polio, pneumococcal infections, measles, mumps, and others. Increasing investments from governments and international organizations, such as the Gates Foundation's USD 1.6 billion support to Gavi in 2025, have bolstered vaccination programs worldwide.
Market Dynamics
Drivers: The market is primarily driven by government support and the expansion of mass vaccination programs. International organizations like Gavi and UNICEF are collaborating with governments for vaccine procurement and immunization initiatives. For example, in January 2025, UNICEF delivered over 9.8 million doses of malaria vaccines to children in 17 endemic African countries, supporting routine immunization programs. Such efforts increase vaccine accessibility, coverage, and demand.
Restraints: Vaccine hesitancy remains a major restraint, particularly in low- and middle-income countries. Safety concerns, myths, misinformation, and mistrust in healthcare systems have hampered adoption. WHO recognized vaccine hesitancy as a top ten global health threat in 2019, and the pandemic has further exacerbated reluctance.
Opportunities: Increasing research and development initiatives provide significant growth opportunities. There is an unmet need for vaccines against highly contagious diseases such as Enterotoxigenic Escherichia coli (ETEC) and Lassa fever. For instance, NIH reported in 2024 that Lassa fever causes approximately 5,000 deaths annually in West Africa, highlighting potential demand for novel vaccines.
Challenges: The lack of cold storage infrastructure poses significant challenges. Improper storage or breaks in the cold chain can lead to vaccine wastage and loss of potency. In 2021, around 2.7 billion people lacked dependable access to vaccines due to insufficient cold chain logistics, underscoring the need for reliable storage systems to support immunization programs.
Market Trends
Combination vaccines are emerging as a key trend, simplifying immunization schedules and increasing coverage. In July 2025, Gavi launched a hexavalent vaccine in Mauritania and Senegal, protecting against six diseases, including diphtheria, tetanus, pertussis, hepatitis B, Hib, and poliomyelitis. Combination vaccines reduce costs and improve compliance in mass vaccination campaigns.
Segmentation Analysis
By Type: The recombinant/conjugate/subunit vaccines segment dominates due to broad applications and high efficiency. Collaborations like Merck and UNICEF's Ebola vaccine stockpile highlight growth potential. Live attenuated vaccines, widely used against measles, mumps, and RSV, are also expanding, exemplified by Codagenix's CodaVax-RSV pediatric trial in 2023. Inactivated vaccines, such as India's Covaxin and Corbevax, are gaining traction due to enhanced stability. mRNA vaccines, including Moderna's Spikevax for children, are expected to grow rapidly due to scalability and regulatory approvals.
By Disease Indication: The viral diseases segment dominates, driven by high prevalence of measles, mumps, rubella, HPV, influenza, and polio. Bacterial vaccines, including Abbott's PneumoShield 14 for pneumococcal infections, are also witnessing significant growth.
By Route of Administration: Oral vaccines lead the market due to ease of administration, supporting mass immunization programs such as the OPV3 coverage of 44% in Papua New Guinea in 2024. Parenteral vaccines are expected to grow steadily, offering systemic immunity and long-term protection.
By Distribution Channel: Government suppliers dominate due to collaborations with operational entities for large-scale immunization campaigns. For example, Panacea Biotec supplied 40 million oral polio doses to UNICEF in 2020, valued at USD 5.2 million. Hospital and retail pharmacies are growing due to accessibility and strategic partnerships, such as Wholehealth Pharmacy's Dose4Dose campaign in Canada.
Regional Outlook
North America: Valued at USD 20.94 billion in 2025, projected to reach USD 22.9 billion in 2026, with strong infrastructure, R&D, and collaborations driving growth. The U.S. holds the largest regional share due to vaccine approvals like Pfizer's ABRYSVO for RSV in infants.
Europe: Substantial share driven by high immunization coverage and government programs. Regulatory approvals, such as Abrysvo for RSV in 2023, help close the vaccine supply gap.
Asia Pacific: Fastest-growing region due to high prevalence of infectious diseases like measles. Gavi reported significant measles outbreaks in East Asia in 2025, boosting vaccine demand.
Latin America & Middle East & Africa: Substantial share supported by vaccination initiatives and WHO programs, such as the Essential Immunization Recovery Plan vaccinating over 5 million children in Africa in 2023.
Competitive Landscape
The market is consolidated, with key players including Sanofi, Merck & Co., Inc., GSK plc., Bharat Biotech, Panacea Biotec, Serum Institute of India, SINOVAC, Haffkine Bio-Pharmaceutical, Bio Farma, AJ Vaccines, and Beijing Institute of Biological Products. Companies focus on new product launches, collaborations, and capacity expansion. For instance, Bharat Biotech collaborated with Bilthoven Biologicals in 2024 to strengthen oral polio vaccine production.
Conclusion
The global pediatric vaccines market is set to grow from USD 46.86 billion in 2025 to USD 50.46 billion in 2026, reaching USD 121.46 billion by 2034 at a CAGR of 11.61%. Growth is driven by government support, mass vaccination programs, R&D initiatives, combination vaccines, and strategic collaborations. North America dominates, while Asia Pacific emerges as the fastest-growing region. Despite challenges like cold chain limitations and vaccine hesitancy, expanding coverage and innovative products will propel the market forward.
Segmentation By Type
- Live Attenuated
- Inactivated
- Recombinant/Conjugate/Subunit
- mRNA Vaccine
- Viral Vectors Vaccines
- Toxoid
- Others
By Disease Indication
- Viral Diseases
- Hepatitis
- Hepatitis A
- Hepatitis B
- Polio
- RSV
- Influenza
- HPV
- Measles/Mumps/Rubella
- Rotavirus
- Shingles (Herpes Zoster)
- Others
- Bacterial Diseases
- Pneumococcal Diseases
- DTP
- Meningococcal Diseases
- Others
By Route of Administration
- Oral
- Parenteral
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
- Germany
- U.K
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Regulatory Scenarios, By Key Countries/Regions
- 4.2. Vaccination Coverage- By Key Countries/ Regions
- 4.3. Government Immunization Programs for Children- By Key Countries/ Regions
- 4.4. Technological Advancements in Pediatric Vaccines Market
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
5. Global Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Live Attenuated
- 5.1.2. Inactivated
- 5.1.3. Recombinant/Conjugate/Subunit
- 5.1.4. mRNA Vaccine
- 5.1.5. Viral Vectors Vaccines
- 5.1.6. Toxoid
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Disease Indication
- 5.2.1. Viral Diseases
- 5.2.1.1. Hepatitis A
- 5.2.1.2. Hepatitis B
- 5.2.1.3. Polio
- 5.2.1.4. RSV
- 5.2.1.5. Influenza
- 5.2.1.6. HPV
- 5.2.1.7. MMR
- 5.2.1.8. Rotavirus
- 5.2.1.9. Shingles
- 5.2.1.10. Others
- 5.2.2. Bacterial Diseases
- 5.2.2.1. Pneumococcal Diseases
- 5.2.2.2. DTP
- 5.2.2.3. Meningococcal Diseases
- 5.2.2.4. Others
- 5.2.1. Viral Diseases
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital & Retail Pharmacies
- 5.4.2. Government Suppliers
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Live Attenuated
- 6.1.2. Inactivated
- 6.1.3. Recombinant/Conjugate/Subunit
- 6.1.4. mRNA Vaccine
- 6.1.5. Viral Vectors Vaccines
- 6.1.6. Toxoid
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Disease Indication
- 6.2.1. Viral Diseases
- 6.2.1.1. Hepatitis A
- 6.2.1.2. Hepatitis B
- 6.2.1.3. Polio
- 6.2.1.4. RSV
- 6.2.1.5. Influenza
- 6.2.1.6. HPV
- 6.2.1.7. MMR
- 6.2.1.8. Rotavirus
- 6.2.1.9. Shingles
- 6.2.1.10. Others
- 6.2.2. Bacterial Diseases
- 6.2.2.1. Pneumococcal Diseases
- 6.2.2.2. DTP
- 6.2.2.3. Meningococcal Diseases
- 6.2.2.4. Others
- 6.2.1. Viral Diseases
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital & Retail Pharmacies
- 6.4.2. Government Suppliers
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Live Attenuated
- 7.1.2. Inactivated
- 7.1.3. Recombinant/Conjugate/Subunit
- 7.1.4. mRNA Vaccine
- 7.1.5. Viral Vectors Vaccines
- 7.1.6. Toxoid
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Disease Indication
- 7.2.1. Viral Diseases
- 7.2.1.1. Hepatitis A
- 7.2.1.2. Hepatitis B
- 7.2.1.3. Polio
- 7.2.1.4. RSV
- 7.2.1.5. Influenza
- 7.2.1.6. HPV
- 7.2.1.7. MMR
- 7.2.1.8. Rotavirus
- 7.2.1.9. Shingles
- 7.2.1.10. Others
- 7.2.2. Bacterial Diseases
- 7.2.2.1. Pneumococcal Diseases
- 7.2.2.2. DTP
- 7.2.2.3. Meningococcal Diseases
- 7.2.2.4. Others
- 7.2.1. Viral Diseases
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital & Retail Pharmacies
- 7.4.2. Government Suppliers
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Live Attenuated
- 8.1.2. Inactivated
- 8.1.3. Recombinant/Conjugate/Subunit
- 8.1.4. mRNA Vaccine
- 8.1.5. Viral Vectors Vaccines
- 8.1.6. Toxoid
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Disease Indication
- 8.2.1. Viral Diseases
- 8.2.1.1. Hepatitis A
- 8.2.1.2. Hepatitis B
- 8.2.1.3. Polio
- 8.2.1.4. RSV
- 8.2.1.5. Influenza
- 8.2.1.6. HPV
- 8.2.1.7. MMR
- 8.2.1.8. Rotavirus
- 8.2.1.9. Shingles
- 8.2.1.10. Others
- 8.2.2. Bacterial Diseases
- 8.2.2.1. Pneumococcal Diseases
- 8.2.2.2. DTP
- 8.2.2.3. Meningococcal Diseases
- 8.2.2.4. Others
- 8.2.1. Viral Diseases
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital & Retail Pharmacies
- 8.4.2. Government Suppliers
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Live Attenuated
- 9.1.2. Inactivated
- 9.1.3. Recombinant/Conjugate/Subunit
- 9.1.4. mRNA Vaccine
- 9.1.5. Viral Vectors Vaccines
- 9.1.6. Toxoid
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Disease Indication
- 9.2.1. Viral Diseases
- 9.2.1.1. Hepatitis A
- 9.2.1.2. Hepatitis B
- 9.2.1.3. Polio
- 9.2.1.4. RSV
- 9.2.1.5. Influenza
- 9.2.1.6. HPV
- 9.2.1.7. MMR
- 9.2.1.8. Rotavirus
- 9.2.1.9. Shingles
- 9.2.1.10. Others
- 9.2.2. Bacterial Diseases
- 9.2.2.1. Pneumococcal Diseases
- 9.2.2.2. DTP
- 9.2.2.3. Meningococcal Diseases
- 9.2.2.4. Others
- 9.2.1. Viral Diseases
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital & Retail Pharmacies
- 9.4.2. Government Suppliers
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Live Attenuated
- 10.1.2. Inactivated
- 10.1.3. Recombinant/Conjugate/Subunit
- 10.1.4. mRNA Vaccine
- 10.1.5. Viral Vectors Vaccines
- 10.1.6. Toxoid
- 10.1.7. Others
- 10.2. Market Analysis, Insights and Forecast - By Disease Indication
- 10.2.1. Viral Diseases
- 10.2.1.1. Hepatitis A
- 10.2.1.2. Hepatitis B
- 10.2.1.3. Polio
- 10.2.1.4. RSV
- 10.2.1.5. Influenza
- 10.2.1.6. HPV
- 10.2.1.7. MMR
- 10.2.1.8. Rotavirus
- 10.2.1.9. Shingles
- 10.2.1.10. Others
- 10.2.2. Bacterial Diseases
- 10.2.2.1. Pneumococcal Diseases
- 10.2.2.2. DTP
- 10.2.2.3. Meningococcal Diseases
- 10.2.2.4. Others
- 10.2.1. Viral Diseases
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital & Retail Pharmacies
- 10.4.2. Government Suppliers
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Merck & Co., Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products & services
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Sanofi.
- 11.2.2.1. Overview
- 11.2.2.2. Products & services
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Bharat Biotech.
- 11.2.3.1. Overview
- 11.2.3.2. Products & services
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. GSK plc.
- 11.2.4.1. Overview
- 11.2.4.2. Products & services
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. SINOVAC
- 11.2.5.1. Overview
- 11.2.5.2. Products & services
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Serum Institute of India Pvt. Ltd.
- 11.2.6.1. Overview
- 11.2.6.2. Products & services
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
- 11.2.7.1. Overview
- 11.2.7.2. Products & services
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Panacea Biotec
- 11.2.8.1. Overview
- 11.2.8.2. Products & services
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. Bio Farma
- 11.2.9.1. Overview
- 11.2.9.2. Products & services
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.10. AJ Vaccines A/S
- 11.2.10.1. Overview
- 11.2.10.2. Products & services
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Strategies
- 11.2.10.6. Financials (Based on Availability)
- 11.2.11. Beijing Institute of Biological Products Co., Ltd.
- 11.2.11.1. Overview
- 11.2.11.2. Products & services
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Strategies
- 11.2.11.6. Financials (Based on Availability)
- 11.2.1. Merck & Co., Inc.
List of Tables
- Table 1: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 2: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
- Table 3: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
- Table 4: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
- Table 5: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 6: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 7: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Region, 2021-2034
- Table 8: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 9: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
- Table 10: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
- Table 11: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
- Table 12: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 13: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 14: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 15: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 16: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
- Table 17: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
- Table 18: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
- Table 19: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 20: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 21: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 22: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 23: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
- Table 24: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
- Table 25: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
- Table 26: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 27: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 28: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 29: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 30: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
- Table 31: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
- Table 32: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
- Table 33: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 34: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 35: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 36: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
- Table 37: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
- Table 38: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
- Table 39: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
- Table 40: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
- Table 41: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
- Table 42: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Pediatric Vaccines Market Revenue Breakdown (USD billion, %), By Region, 2025 & 2034
- Figure 2: Global Pediatric Vaccines Market Value Share (%), By Type, 2025 & 2034
- Figure 3: Global Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025 & 2034
- Figure 4: Global Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025 & 2034
- Figure 5: Global Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025 & 2034
- Figure 6: Global Pediatric Vaccines Market Value Share (%), By Region, 2025 & 2034
- Figure 7: North America Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
- Figure 8: North America Pediatric Vaccines Market Value Share (%), By Type, 2025
- Figure 9: North America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
- Figure 10: North America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
- Figure 11: North America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 12: North America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
- Figure 13: North America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 14: North America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
- Figure 15: North America Pediatric Vaccines Market Value (USD billion), By Country, 2025 & 2034
- Figure 16: North America Pediatric Vaccines Market Value Share (%), By Country, 2025
- Figure 17: Europe Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
- Figure 18: Europe Pediatric Vaccines Market Value Share (%), By Type, 2025
- Figure 19: Europe Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
- Figure 20: Europe Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
- Figure 21: Europe Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 22: Europe Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
- Figure 23: Europe Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 24: Europe Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
- Figure 25: Europe Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 27: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
- Figure 28: Asia Pacific Pediatric Vaccines Market Value Share (%), By Type, 2025
- Figure 29: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
- Figure 30: Asia Pacific Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
- Figure 31: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 32: Asia Pacific Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
- Figure 33: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 34: Asia Pacific Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
- Figure 35: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
- Figure 38: Latin America Pediatric Vaccines Market Value Share (%), By Type, 2025
- Figure 39: Latin America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
- Figure 40: Latin America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
- Figure 41: Latin America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 42: Latin America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
- Figure 43: Latin America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 44: Latin America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
- Figure 45: Latin America Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
- Figure 48: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Type, 2025
- Figure 49: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
- Figure 50: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
- Figure 51: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
- Figure 52: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
- Figure 53: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
- Figure 54: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
- Figure 55: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 56: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 57: Global Pediatric Vaccines Market Share (%), By Company, 2025
